| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |